



Formula No. 15

wherein m and n are 1 to 5;

X designates a terminal carboxy acid, amide or alcohol group;

R⁵ is (D)- or (L)-Phe or (D)- or (L)-Ala;

R⁷ is (D)- or (L)-Trp, (D)- or (L)-Phe, (D)- or (L)-1Nal or (D)- or (L)-2Nal, or Tyr;

R¹⁰ is Thr, Gly, Abu, Ser, Cys, Val, (D)- or (L)-Ala, or (D)- or (L)-Phe;

R¹² is Gly, Val, (D)- or (L)-Phe, or is absent;

R¹³ is (D)- or (L)-Phe or (D)- or (L)-Ala; and

Y² is amide, thioether, thioester or disulfide.

14. The backbone cyclized somatostatin analog of claim 13 wherein:

R⁵ is Phe;

R⁷ is Phe;

R¹⁰ is Thr;

R¹² is Gly, Val, (D)- or (L)-Phe, or is absent;

R¹³ is Phe; and

Y² is amide.

15. The backbone cyclized somatostatin analog of claim 1 having the formula:

Phe(N2)-Tyr-(D)2Nal-Lys-Val-Gly(C2)-Thr-X;

Phe(N2)-Tyr-(D)Trp-Lys-Val-Gly(C2)-2Nal-X;

Phe(N2)-Tyr-(D)Trp-Lys-Val-Val-Gly(C2)-X;

Phe(N2)-Tyr-(D)Trp-Lys-Ser-2Nal-Gly(C2)-X;

Phe(N2)-Phe-(D)Trp-Lys-Thr-2Nal-Gly(C2)-X;

GABA*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-X;

Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X;

~~en~~ Phe(C3)-Cys*-Phe-(D)Trp-Lys-Thr-Cys*-Phe(N3)-X

(D)Phe-Cys*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(S2)-X; or

Galactose-Dab*-Phe-Trp-(D)Trp-Lys-Thr-Phe-Gly(C3)-X;

wherein X designates a terminal carboxy acid, amide, or alcohol group; the asterisk denotes that the bridging group is connected between the N^α-ω-functionalized derivative of an amino acid and the N-terminus of the peptide or the side chain of the Cys residue.